Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
211At-bisB10-biotin
- Development stage
- Preclinical
- Lead developer
- University of Washington
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
211At-bisB10-biotin is a novel radiolabeled small molecule conjugate consisting of a bis-closo-decaborate(4-) (bisB10) boron cage structure linked to biotin and radiolabeled with the alpha-emitting radionuclide astatine-211 (211At). Developed by researchers at the University of Washington, Fred Hutch Cancer Center, and the University of Miami, this compound is designed for targeted alpha therapy (TAT) using biotin-streptavidin pretargeting systems. The bisB10 boron cage acts as a dual nucleophilic reagent that intramolecularly traps oxidized astatine, stabilizing the boron-astatine bond and reducing in vivo oxidative deastatination. This design improves pharmacokinetics and reduces off-target toxicity associated with free astatine accumulation in non-target tissues.
- Other names
- 211At-bisB10-biotin211At-labeled bis-boron cage biotin derivativeastatine-211-bisB10-biotinastatine211-bisB10-biotinastatine 211-bisB10-biotin
Beyond the preview
Go deeper on 211At-bisB10-biotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 211At-bisB10-biotin.